136 related articles for article (PubMed ID: 20949619)
1. MET mutations in cancers of unknown primary origin (CUPs).
Stella GM; Benvenuti S; Gramaglia D; Scarpa A; Tomezzoli A; Cassoni P; Senetta R; Venesio T; Pozzi E; Bardelli A; Comoglio PM
Hum Mutat; 2011 Jan; 32(1):44-50. PubMed ID: 20949619
[TBL] [Abstract][Full Text] [Related]
2. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
[TBL] [Abstract][Full Text] [Related]
3. Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion.
Lorenzato A; Olivero M; Patanè S; Rosso E; Oliaro A; Comoglio PM; Di Renzo MF
Cancer Res; 2002 Dec; 62(23):7025-30. PubMed ID: 12460923
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas.
Di Renzo MF; Olivero M; Martone T; Maffe A; Maggiora P; Stefani AD; Valente G; Giordano S; Cortesina G; Comoglio PM
Oncogene; 2000 Mar; 19(12):1547-55. PubMed ID: 10734314
[TBL] [Abstract][Full Text] [Related]
5. MET receptor is overexpressed but not mutated in oral squamous cell carcinomas.
Morello S; Olivero M; Aimetti M; Bernardi M; Berrone S; Di Renzo MF; Giordano S
J Cell Physiol; 2001 Dec; 189(3):285-90. PubMed ID: 11748586
[TBL] [Abstract][Full Text] [Related]
6. Alterations of APC, c-met, and p53 genes in tumor tissue and serum of patients with gastric cancers.
Wang JY; Hsieh JS; Chen CC; Tzou WS; Cheng TL; Chen FM; Huang TJ; Huang YS; Huang SY; Yang T; Lin SR
J Surg Res; 2004 Aug; 120(2):242-8. PubMed ID: 15234219
[TBL] [Abstract][Full Text] [Related]
7. A novel germ line juxtamembrane Met mutation in human gastric cancer.
Lee JH; Han SU; Cho H; Jennings B; Gerrard B; Dean M; Schmidt L; Zbar B; Vande Woude GF
Oncogene; 2000 Oct; 19(43):4947-53. PubMed ID: 11042681
[TBL] [Abstract][Full Text] [Related]
8. Novel mutations of the MET proto-oncogene in papillary renal carcinomas.
Schmidt L; Junker K; Nakaigawa N; Kinjerski T; Weirich G; Miller M; Lubensky I; Neumann HP; Brauch H; Decker J; Vocke C; Brown JA; Jenkins R; Richard S; Bergerheim U; Gerrard B; Dean M; Linehan WM; Zbar B
Oncogene; 1999 Apr; 18(14):2343-50. PubMed ID: 10327054
[TBL] [Abstract][Full Text] [Related]
9. Regulation of the wild-type and Y1235D mutant Met kinase activation.
Cristiani C; Rusconi L; Perego R; Schiering N; Kalisz HM; Knapp S; Isacchi A
Biochemistry; 2005 Nov; 44(43):14110-9. PubMed ID: 16245927
[TBL] [Abstract][Full Text] [Related]
10. Interplay between scatter factor receptors and B plexins controls invasive growth.
Conrotto P; Corso S; Gamberini S; Comoglio PM; Giordano S
Oncogene; 2004 Jul; 23(30):5131-7. PubMed ID: 15184888
[TBL] [Abstract][Full Text] [Related]
11. MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin.
Stella GM; Benvenuti S; Gentile A; Comoglio PM
EBioMedicine; 2017 Oct; 24():34-42. PubMed ID: 29037604
[TBL] [Abstract][Full Text] [Related]
12. Gastric cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane domain deletion.
Asaoka Y; Tada M; Ikenoue T; Seto M; Imai M; Miyabayashi K; Yamamoto K; Yamamoto S; Kudo Y; Mohri D; Isomura Y; Ijichi H; Tateishi K; Kanai F; Ogawa S; Omata M; Koike K
Biochem Biophys Res Commun; 2010 Apr; 394(4):1042-6. PubMed ID: 20331976
[TBL] [Abstract][Full Text] [Related]
13. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients.
Salvi A; Marchina E; Benetti A; Grigolato P; De Petro G; Barlati S
Int J Oncol; 2008 Aug; 33(2):271-6. PubMed ID: 18636147
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional targets of hepatocyte growth factor signaling and Ki-ras oncogene activation in colorectal cancer.
Seiden-Long IM; Brown KR; Shih W; Wigle DA; Radulovich N; Jurisica I; Tsao MS
Oncogene; 2006 Jan; 25(1):91-102. PubMed ID: 16158056
[TBL] [Abstract][Full Text] [Related]
15. Met receptor overexpression and oncogenic Ki-ras mutation cooperate to enhance tumorigenicity of colon cancer cells in vivo.
Long IS; Han K; Li M; Shirasawa S; Sasazuki T; Johnston M; Tsao MS
Mol Cancer Res; 2003 Mar; 1(5):393-401. PubMed ID: 12651912
[TBL] [Abstract][Full Text] [Related]
16. Targeting the MET oncogene in cancer and metastases.
Stella GM; Benvenuti S; Comoglio PM
Expert Opin Investig Drugs; 2010 Nov; 19(11):1381-94. PubMed ID: 20868306
[TBL] [Abstract][Full Text] [Related]
17. Identification of a novel germline MET mutation in dogs.
Liao AT; McMahon M; London CA
Anim Genet; 2006 Jun; 37(3):248-52. PubMed ID: 16734685
[TBL] [Abstract][Full Text] [Related]
18. Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.
MacDougall CA; Vargas M; Soares CR; Holzer RG; Ide AE; Jorcyk CL
Prostate; 2005 Jul; 64(2):139-48. PubMed ID: 15678502
[TBL] [Abstract][Full Text] [Related]
19. Massively-parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary.
Tothill RW; Li J; Mileshkin L; Doig K; Siganakis T; Cowin P; Fellowes A; Semple T; Fox S; Byron K; Kowalczyk A; Thomas D; Schofield P; Bowtell DD
J Pathol; 2013 Dec; 231(4):413-23. PubMed ID: 24037760
[TBL] [Abstract][Full Text] [Related]
20. Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers.
Vécsey-Semjén B; Becker KF; Sinski A; Blennow E; Vietor I; Zatloukal K; Beug H; Wagner E; Huber LA
Oncogene; 2002 Jul; 21(30):4646-62. PubMed ID: 12096341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
